AstraZeneca/Oxford apply for European Union approval of COVID vaccine

European Medicines Agency asked to approve AstraZeneca-Oxford vaccine

Vaccinations in Australia are set to begin in mid-February with the rollout to be accompanied by a public information campaign on the safety of vaccines.

British-Swedish pharmaceutical company along with the Oxford University have applied for a market approval of their COVID-19 vaccine in the EU, the European Medicines Agency (EMA) said in an announcement on Tuesday.

The Amsterdam-based regulator said that its assessment of the vaccine would "proceed under an accelerated timeline".

The EMA already authorized the Pfizer / BioNTech COVID-19 vaccine on December 21 and the Moderna vaccine on January 6, for which the European Commission immediately gave the green light.

A conditional marketing authorisation results in a fast-tracked approval during public health emergencies valid throughout all European Union member states.

Earlier, Malapitan said that the city government earmarked a budget of P125 million for the procurement of COVID-19 vaccines.

The President of the European Commission, Ursula von der Leyen also welcomed the news on Twitter. "Once the vaccine receives a positive scientific opinion, we will work full speed to authorise its use in Europe".

The Oxford/AstraZeneca vaccine was approved for use in the United Kingdom late last month.

AstraZeneca's vaccine has been approved in countries including Argentina, Britain, El Salvador and India.

The AstraZeneca COVID-19 vaccine requires two doses for it to be effective.

The update comes a month after both Pfizer and BioNTech, and later Moderna, said the EMA had informed the companies that some evaluation documents had been accessed in the cyberattack on the agency.



Other news